As of 2026-03-29, the EV/EBITDA ratio of AnaptysBio Inc (ANAB) is -64.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AnaptysBio's latest enterprise value is 1,688.58 mil USD. AnaptysBio's TTM EBITDA according to its financial statements is -26.01 mil USD. Dividing these 2 quantities gives us the above AnaptysBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.1x - 14.1x | 13.9x |
| Forward P/E multiples | 8.5x - 15.1x | 12.3x |
| Fair Price | (10.51) - (14.05) | (13.18) |
| Upside | -118.3% - -124.5% | -123.0% |
| Date | EV/EBITDA |
| 2026-03-20 | -70.41 |
| 2026-03-19 | -73.02 |
| 2026-03-18 | -73.02 |
| 2026-03-17 | -75.86 |
| 2026-03-16 | -73.08 |
| 2026-03-13 | -73.12 |
| 2026-03-12 | -71.99 |
| 2026-03-11 | -72.96 |
| 2026-03-10 | -70.02 |
| 2026-03-09 | -67.47 |
| 2026-03-06 | -62.73 |
| 2026-03-05 | -64.79 |
| 2026-03-04 | -68.41 |
| 2026-03-03 | -59.87 |
| 2026-03-02 | -62.17 |
| 2026-02-27 | -62.33 |
| 2026-02-26 | -63.50 |
| 2026-02-25 | -62.39 |
| 2026-02-24 | -62.73 |
| 2026-02-23 | -61.49 |
| 2026-02-20 | -61.38 |
| 2026-02-19 | -62.78 |
| 2026-02-18 | -62.08 |
| 2026-02-17 | -60.83 |
| 2026-02-13 | -60.15 |
| 2026-02-12 | -62.16 |
| 2026-02-11 | -62.55 |
| 2026-02-10 | -57.01 |
| 2026-02-09 | -56.69 |
| 2026-02-06 | -56.45 |
| 2026-02-05 | -54.42 |
| 2026-02-04 | -54.95 |
| 2026-02-03 | -58.08 |
| 2026-02-02 | -57.34 |
| 2026-01-30 | -53.88 |
| 2026-01-29 | -54.37 |
| 2026-01-28 | -53.93 |
| 2026-01-27 | -56.45 |
| 2026-01-26 | -53.56 |
| 2026-01-23 | -54.03 |
| 2026-01-22 | -53.79 |
| 2026-01-21 | -53.08 |
| 2026-01-20 | -52.56 |
| 2026-01-16 | -51.97 |
| 2026-01-15 | -52.67 |
| 2026-01-14 | -57.03 |
| 2026-01-13 | -54.67 |
| 2026-01-12 | -55.67 |
| 2026-01-09 | -50.85 |
| 2026-01-08 | -49.89 |